Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.

Shahid Ahmed,Deborah H. Anderson,Haji I. Chalchal,Lynn Dwernychuk,Dilip Gill,Josh Gitlin,Austin Hammond,Rani Kanthan,Duc Le,J. Lim,Rajan Rakheja,Nazmi Sari,Franco J. Vizeacoumar,Adnan Zaidi,Michael A. J. Moser

Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.

2021

Shahid Ahmed
Deborah H. Anderson
Haji I. Chalchal
Lynn Dwernychuk
Dilip Gill
Josh Gitlin
Austin Hammond
Rani Kanthan
Duc Le
J. Lim
Rajan Rakheja
Nazmi Sari
Franco J. Vizeacoumar
Adnan Zaidi
Michael A. J. Moser

TPS147Background: Patients with mCRC generally have a limited life expectancy, however, a small number of patients with liver-only mCRC could be cured following metastasectomy. In highly selected p...

Keywords:

Bevacizumab
Colorectal cancer
Oncology
Internal medicine
Metastasectomy
FOLFOXIRI
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations